ASPARTAME
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 294.0 | -0.3 | 3 | 5 | 119.0 | 7 | 0.36 |
- CAS
- 22839470
- UNII
- Z0H242BBR1
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 74 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT01200940 | 2010-06-01 | Metabolic Effects of Non-Nutritive Sweeteners | Phase 1/Phase 2 | Recruiting |
| NCT00731510 | 2008-06-01 | MEDEX Hidden Valley 2008 | Phase 4 | Active, Not Recruiting |
(Browse) Purchasable Analogs in ZINC
Functions of Aspartame
| Nutrs - Nutritive Sweetener |
Regulatory Status of Aspartame
| Reg - Food additives for which a petition has been filed and a regulation issued. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Buccal | Patch, Controlled Release | 1.1MG |
| Oral | Capsule | 0.8MG |
| Oral | Granule, Effervescent | |
| Oral | Granule, For Suspension | 35MG |
| Oral | Powder | 45% |
| Oral | Powder, For Oral Solution | 233MG |
| Oral | Powder, For Oral Suspension | 4.8% |
| Oral | Powder, For Reconstitution | 0.25% |
| Oral | Powder, For Solution | 4.7% |
| Oral | Suspension | 1% |
| Oral | Syrup | 0.01% |
| Oral | Tablet | 20MG |
| Oral | Tablet (Immed./comp. Release), Film Coated | 5.1MG |
| Oral | Tablet (Immed./comp. Release), Uncoated, Chewable | 65MG |
| Oral | Tablet (Immed./comp. Release), Uncoated, Effervescent | 30MG |
| Oral | Tablet, Dispersible | 2.5MG |
| Oral | Tablet, Film Coated | 20MG |
| Oral | Tablet, Orally Disintegrating | 36MG |
| Oral | Tablet, Orally Disintegrating, Delayed Release | 9MG |
| Oral | Troche | 6.1MG |
| Sublingual | Tablet | 8MG |
| Transdermal | Patch, Electrically Controlled | 9.5MG |